Actero Middle East is pleased to announce the launch of two new molecules to the Iranian market. Doxorubicin ACTe 10 mg and 50 mg and Etoposide ACTe 100 mg/5ml. Doxorubicin ACTe 10mg and 50mg injections are the generic version of Adriamycin, a chemotherapy medication used to treat a broad range of cancers including breast cancer, bladder cancer, Kaposi’s sarcoma, lymphoma, and acute lymphocytic leukemia. Etoposide ACTe 100 mg/5ml injections are the generic version of Etopophos, a chemotherapy medication used to treat a broad range of cancers including testicular cancer, lung cancer, lymphoma, leukemia, neuroblastoma, and ovarian cancer.

“Doxorubicin ACTe and Etoposide ACTe are the two latest products in our growing oncology portfolio. With these new additions, we aim to gain the trust of all stakeholders and continue building a portfolio where every Actero medicine stands for reliability.”

CEO of Actero

Actero is a pharmaceutical company specialized in high-quality oncology products and has over 15 products under development or pending Ministry of Health approval.